logo-loader
CytoDyn

CytoDyn to apply to enter phase 2 clinical studies with PRO140 to treat colon cancer

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors that the biotech announced strong preclinical results from a series of completed studies of its colon cancer treatment leronlimab.

Pourhassan says because of this, the company will be applying to the FDA to enter phase 2 clinical studies with PRO140 to treat colon cancer by as early as next week.

Quick facts: CytoDyn

Price: $0.43

Market: OTCQB
Market Cap: $162.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

1 week, 3 days ago

2 min read